Experimental Skin Cream Shows Promise in Reducing Biological Skin Age

An experimental skin cream has demonstrated the potential to reduce biological skin age and inflammation in an early human trial, according to preliminary data released by its developer, Rubedo Life Sciences. The investigational treatment, RLS-1496, was tested on patients with eczema and other skin conditions.

In an analysis of 11 paired skin samples, four weeks of treatment with RLS-1496 was associated with an average decrease of 2.1 years in measured epigenetic skin age, a metric based on age-related changes in DNA. Researchers also observed a 10% increase in structural collagen in skin samples and a reduction in several blood markers linked to inflammation.

Dr. Frederick Beddingfield, CEO of Rubedo Life Sciences, described the early findings as significant and warranting further investigation. He believes the approach targets cellular aging by clearing senescent cells—damaged cells that cease dividing but can promote inflammation. The drug targets a protein called GPX4, which aids cellular stress response, with researchers studying if blocking it can eliminate aged cells while helping healthier cells survive.

"This is one of the few drugs developed for aging in general and with AI to show positive data in humans in multiple indications and to show a reduction in skin age," Beddingfield stated.

In a separate early-stage study involving 22 patients with actinic keratosis, a condition characterized by rough, precancerous skin patches from sun exposure, RLS-1496 reportedly led to a 49% average reduction in lesions after 28 days of treatment. This study compared treated forearms to untreated ones, rather than using a placebo cream.

Rubedo Life Sciences is also initiating an early-stage trial for RLS-1496 to address androgenetic alopecia, commonly known as pattern hair loss. The company anticipates that potential FDA approval for therapeutic uses could be three to four years away, contingent on larger clinical trials.

However, the preliminary findings have limitations. The skin-aging analysis involved a small sample size, and the study measured biological signs of aging in the skin rather than observable age reduction or improved skin function. The treatment duration was limited to four weeks, and the long-term persistence of the observed changes remains unknown. The studies were sponsored by Rubedo, and the findings have not yet been published in a peer-reviewed journal.

The company reported minimal skin irritation and very few instances of the drug being detected in participants' blood following topical application. Beddingfield indicated that future trials will involve longer treatment periods.

While FDA prescription approval is projected to take several years, non-prescription cosmetic formulations based on similar mechanisms could potentially become available within a year.